摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-benzylpyridazin-3-amine | 1356731-82-2

中文名称
——
中文别名
——
英文名称
6-benzylpyridazin-3-amine
英文别名
6-Benzylpyridazin-3-amine
6-benzylpyridazin-3-amine化学式
CAS
1356731-82-2
化学式
C11H11N3
mdl
——
分子量
185.228
InChiKey
UFUBQPZTPSJGMW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    51.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • MRGX2 ANTAGONISTS
    申请人:GlaxoSmithKline Intellectual Property Development Limited
    公开号:US20220112174A1
    公开(公告)日:2022-04-14
    This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    本发明涉及按照式(I)的新化合物,这些化合物是MrgX2的拮抗剂,包含它们的药物组合物,以及它们在治疗MrgX2介导的疾病和疾病中的应用。
  • [EN] DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS<br/>[FR] DÉRIVÉS D'OXADIAZOLE ET DE PYRIDAZINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPIE
    申请人:SANOFI SA
    公开号:WO2012011081A1
    公开(公告)日:2012-01-26
    The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a -CH- group; X1 represents a nitrogen atom or a -CH=CH- group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1 -C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a -(C3-C10)cycloalkyl- group; Y represents a -(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1 -C6)alkoxy group; Z1 is absent or represents an -NH- function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.
    本发明涉及公式(I)的化合物:其中:n等于0或1;D代表氧原子或键;W代表氮原子或-CH-基团;X1代表氮原子或-CH=CH-基团;X2代表氧原子或氮原子;X3代表氧原子或氮原子;其中X1、X2、X3中的一个不是氮原子,X2和X3不同时是氧原子;R1、R2不存在或代表(i)彼此独立的氢原子或(C1-C4)烷基;(ii)R1和R2可能与它们附着的碳原子形成-(C3-C10)环烷基-基团;Y代表-(C3-C10)环烷基、芳基或芳氧基团,所述基团可选地用一个或多个卤原子或(C1-C6)烷氧基取代;Z1不存在或代表-NH-功能;Z2和Z3如本说明书所定义。本发明还涉及制备公式(I)化合物的方法,包含它们的组合物以及在治疗学中的应用。
  • DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
    申请人:Sanofi
    公开号:US20130137691A1
    公开(公告)日:2013-05-30
    The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a —CH— group; X1 represents a nitrogen atom or a —CH═CH— group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1-C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a —(C3-C10)cycloalkyl- group; Y represents a —(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1-C6)alkoxy group; Z1 is absent or represents an —NH— function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.
    本发明涉及公式(I)的化合物: 其中: n等于0或1; D代表氧原子或键; W代表氮原子或—CH—基团; X1代表氮原子或—CH═CH—基团; X2代表氧原子或氮原子; X3代表氧原子或氮原子; X1、X2、X3中的一个不是氮原子,X2和X3同时不是氧原子; R1,R2不存在或代表(i)彼此独立的氢原子或(C1-C4)烷基,(ii)R1和R2可以与它们附着的碳原子形成—(C3-C10)环烷基-基团; Y代表—(C3-C10)环烷基-、芳基或芳氧基团,这些基团可以选择性地被一个或多个卤素原子或(C1-C6)烷氧基置换; Z1不存在或代表—NH—功能; Z2和Z3如本说明中所定义。 本发明还涉及制备公式(I)的化合物的方法、含有它们的组合物以及它们在治疗学中的应用。
  • WO2019183587A5
    申请人:——
    公开号:WO2019183587A5
    公开(公告)日:2022-03-30
  • COMPOUNDS AND USES THEREOF
    申请人:Yumanity Therapeutics, Inc.
    公开号:EP3768269A1
    公开(公告)日:2021-01-27
查看更多